



Annual report 2015

## PharmaDanica A/S

Vassingerødvej 9, 3540 Lyngby, Denmark  
CVR no. 19 05 60 07

Approved at General Meeting -26 /05/ 2016  
Chairman:

A handwritten signature in blue ink, consisting of several overlapping loops and strokes, positioned below the text 'Chairman:'. The signature is somewhat abstract and difficult to decipher.



## **Contents**

Statement by the Board of Directors and the Executive Board	2
Independent Auditor's Report	3
Company details	5
Financial statements for the period 1 January – 31 December	
Accounting policies	6
Income statement	8
Balance sheet	9
Notes to the Annual Report	11



## **Statement by the Board of Directors and the Executive Board**

The Board of Directors and the Executive Board have today discussed and approved the annual report of PharmaDanica A/S for the financial year 1 January - 31 December 2015.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

It is our opinion that the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January - 31 December 2015.

We recommend that the annual report be approved at the annual general meeting.


Lynge, 30 March 2016

Executive Board:



---


Kim Erik Ginnerup  
CEO



---


Poul Lindof  
CFO

Board of Directors:



---

Jean-Marc Pierre Rene  
Leccia  
Chairman



---

Denis Georges Fernand  
Maurice



---

Kim Erik Ginnerup



---

Eric Pierre Jean Muris



## **Independent Auditor's Report**

To the Shareholder of PharmaDanica A/S

We have audited the Financial Statements of PharmaDanica A/S for the financial year 1 January - 31 December 2015, which comprise income statement, balance sheet, notes and summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.

### **Management's Responsibility for the Financial Statements**

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on the Financial Statements based on our audit. We conducted our audit in accordance with International Standards on Auditing and additional requirements under Danish audit regulation. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the Financial Statements are free from material misstatement.

An audit involves performing audit procedures to obtain audit evidence about the amounts and disclosures in the Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation of Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Management, as well as evaluating the overall presentation of the Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Our audit has not resulted in any qualification.



## **Independent Auditor's Report (continued)**

### **Opinion**

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2015 and of the results of the Company operations for the financial year 1 January - 31 December 2015 in accordance with the Danish Financial Statements Act.

Copenhagen, 30 March 2016

**PricewaterhouseCoopers**

Statsautoriseret Revisionspartnerselskab

*CVR-nr. 33 77 12 31*

Rasmus Friis Jørgensen  
State Authorised Public Accountant

Henrik Ødegaard  
State Authorised Public Accountant



## **Company details**

**PharmaDanica A/S**  
Vassingerødvej 9  
3540 Lyngø  
Denmark  
[www.missionpharma.com](http://www.missionpharma.com)

CVR no.: 19 05 60 07  
Financial year: 1 January - 31 December  
Established: 1 January 1996  
Registered office: Allerød, Denmark

### **Board of Directors**

Jean-Marc Pierre Rene Leccia (Chairman)  
Denis Georges Fernand Maurice  
Eric Pierre Jean Muris  
Kim Erik Ginnerup

### **Executive Board**

Kim Erik Ginnerup (CEO)  
Poul Lindof (CFO)

### **Auditors**

PricewaterhouseCoopers  
Statsautoriseret Revisionspartnerselskab  
Strandvejen 44  
2900 Hellerup, Denmark

### **Activity**

The Company's activity is to conduct trade and industry.

### **Ultimate Danish parent company**

The company's accounts are consolidated in the accounts of Missionpharma Group ApS.



## **Financial statements for the period 1 January - 31 December**

### **Accounting policies**

The annual report of PharmaDanica A/S for 2015 has been prepared in accordance with the provisions applying to reporting class B enterprises under the Danish Financial Statements Act.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

The Annual Report 2015 is presented in DKK.

### **Income statement**

#### **Other external expenses**

Other external expenses include expenses for administration, etc.

#### **Financial income and expenses**

Financial income and expenses are recognized in the income statement at the amounts relating to the financial year. Financial income and expenses include interest income and expenses, and adjustment relating to foreign currency transactions.

#### **Tax**

Income tax expense comprises current tax on the estimated taxable income and the adjustment of deferred tax less the amount of net tax related to equity movement.

Current and deferred tax relating to equity is recognized directly in equity.

The parent and all Danish group entities are jointly taxed. The Danish income tax charge is allocated between profit-making and loss-making Danish entities in proportion to their taxable income (full allocation method).

### **Balance sheet**

#### **Other investments**

Other investments are measured at market price. Capital gains and loss are recognized in income statement.

#### **Receivables**

Receivables are measured at amortized cost. Write-down is made for bad debt losses, based on an individual assessment.



## **Financial statements for the period 1 January - 31 December**

### **Accounting policies**

#### **Corporation tax**

Current tax payables and current tax receivables are recognized in the balance sheet as the estimated tax charge in respect of the taxable income of the year, adjusted for tax on prior years' taxable income and tax paid in advance.

Provisions for deferred tax are calculated using the expected tax rate by elimination of the temporary differences between carrying amounts and tax values, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income, and temporary differences on non-amortizable goodwill.

Deferred tax assets, including the tax value of deferrable taxable losses, are recognized at the value at which they are expected to be utilized, either through elimination against tax on future earnings or a set-off against deferred tax liabilities within the same legal tax entity.

#### **Liabilities**

Financial liabilities are recognized on the raising of the loan at the cost, corresponding to the proceeds received net of transaction costs incurred. The financial liabilities are subsequently measured at amortized cost.

Other liabilities are measured at the net realizable value.





## Financial statements for the period 1 January - 31 December

### Income statement

DKK	Note	2015	2014
Other external expenses		<u>-14,304</u>	<u>-20,623</u>
<b>Operating result before net financials and tax</b>		<b>-14,304</b>	<b>-20,623</b>
Other financial income	1	2,515,695	8
Other financial expenses	2	<u>-2,371</u>	<u>-31,860</u>
<b>Profit before tax</b>		<b>2,499,020</b>	<b>-52,475</b>
Tax on profit		<u>3,919</u>	<u>12,856</u>
<b>Profit for the year</b>		<b><u>2,502,939</u></b>	<b><u>-39,619</u></b>
<b>Proposed profit appropriation</b>			
Retained earnings		<u>2,502,939</u>	<u>-39,619</u>



## Financial statements for the period 1 January - 31 December

### Balance sheet

DKK	Note	2015	2014
<b>ASSETS</b>			
<b>Non-current assets</b>			
<b>Financial assets</b>			
Other investments		2,666,667	0
<b>Total non-current assets</b>		<u>2,666,667</u>	<u>0</u>
<b>Current assets</b>			
Receivables from group companies		4,098	12,856
<b>Cash</b>		829,323	984,292
<b>Total current assets</b>		<u>833,421</u>	<u>997,148</u>
<b>TOTAL ASSETS</b>		<u><u>3,500,088</u></u>	<u><u>997,148</u></u>



## Financial statements for the period 1 January - 31 December

### Balance sheet

DKK	Note	2015	2014
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>	<b>3</b>		
Share capital		1,000,000	1,000,000
Retained earnings		<u>2,492,287</u>	<u>-10,652</u>
<b>Total equity</b>		<u>3,492,287</u>	<u>989,348</u>
<b>Current liabilities</b>			
Other payables		<u>7,801</u>	<u>7,800</u>
<b>Total liabilities</b>		<u>7,801</u>	<u>7,800</u>
<b>TOTAL EQUITY AND LIABILITIES</b>		<u>3,500,088</u>	<u>997,148</u>
<b>Contingent liabilities and other financial obligations</b>	<b>4</b>		
<b>Consolidated accounts</b>	<b>5</b>		



## Notes to the Annual Report

DKK	2015	2014	
<b>1 Other financial income</b>			
Other financial income	-	8	
Revaluation of shares	2,515,695	-	
	<u>2,515,695</u>	<u>8</u>	
<b>2 Other financial expenses</b>			
Interest payables, group entities	0	31,710	
Interest payables, exchange losses and similar expenses	2,371	150	
	<u>2,371</u>	<u>31,860</u>	
<b>3 Equity</b>			
DKK	Share capital	Retained earnings	Total
Equity at 1 January	1,000,000	-10,652	989,348
Profit for the year	0	2,502,939	2,502,939
<b>Equity at 31 December</b>	<u>1,000,000</u>	<u>2,492,287</u>	<u>3,492,287</u>

The share capital is divided into 1,000 shares each DKK 1,000.  
No shares have separate privileges.

#### 4 Contingent liabilities and other financial obligations

##### Contingent liabilities

The company is jointly taxed with the other Danish entities in the Missionpharma Group. As a wholly-owned subsidiary, the company is jointly and severally liable, together with the other jointly taxed entities, for Danish income taxes and withholding taxes on dividends, interest and royalties within the group of jointly taxed entities. Any subsequent adjustments of the joint taxable income or withholding taxes may result in an increase of the company's liability.

##### Guarantees

The Group companies (PharmaDanica A/S, Mifamed ApS, Missionpharma Group ApS, Missionpharma A/S, and Missionpharma Properties A/S) are jointly and severally liable for a total credit and facility line of DKK 237 million.



## **Notes to the Annual Report**

### **5 Consolidated accounts**

The company's ultimate Danish parent company at December 31, 2015, which prepares consolidated accounts in which the Company is a subsidiary is Missionpharma Group ApS, Denmark. The consolidated financial statements are available at the following address:

Missionpharma Group ApS, Vassingerøedvej 9, 3540 Lyngø.

The Company's ultimate parent company at December 31, 2015, which prepares consolidated accounts in which the company is a subsidiary, is Toyota Tsusho Corporation, Japan. The consolidated financial statements are available at the following address:

Toyota Tsusho Corporation, 9-8 Meieki 4-chome, Nagoya-shi, Aichi-ken, Japan.

